IL-12 and IL-17 are leading candidates, given previous work showing that IL-17 can affect synaptic plasticity and microglial activation in a model of multiple sclerosis44, IL-12 is involved in AD pathology and associated cognitive deficits10–13, microglial IL-12 is upregulated in AD-like transgenic mice14, and targeting the IL-12p40 subunit can reduce amyloid pathology and cognitive deficits in these animals14. Here, IL17A is linked to amyloidosis.